CrushSCI.com
103.9平均天数
99中位天数
12最短天数
245最长天数
2,6642025发文量

Paper Review Records

全部论文审稿周期

11 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

163 天

ctDNA-Based MRD Detection in Stage III NSCLC Treated With Chemoradiotherapy and Durvalumab

作者
Henrik Horndalsveen; Vilde Drageset Haakensen; Tesfaye Madebo; Bjørn Henning Grønberg; Tarje Onsøien Halvorsen; Maria Moksnes Bjaanæs; Britina Kjuul Danielsen; Mari Børve; Solveig Kokkvoll; Tonje Sofie Dalen Boda; Åsa Kristina Öjlert; Åslaug Helland展开收起
作者单位
Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Department of Oncology, Oslo University Hospital, Oslo, Norway; Department of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Pulmonology, Stavanger University Hospital, Stavanger, Norway; Department of Clinical Science, University of Bergen, Bergen, Norway; Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway; Department of Oncology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway展开收起
PDF源文件 DOI 网页
43 天

First-Line Integration of Local Ablative Therapy With EGFR Tyrosine Kinase Inhibitors in Advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis

作者
Leonardo Brunetti; Giacomo Colella; Giuseppina Rita Di Fazio; Giulia La Cava; Valentina Santo; Federica Pecci; Julia K. Rotow; Jessica R. Bauman; Amin H. Nassar; Elio Adib; Abdul Rafeh Naqash; Marco Tagliamento; Roberto Ferrara; Fabrizio Citarella; Marco Russano; Biagio Ricciuti; Corinne Faivre-Finn; Lizza E.L. Hendriks; Antonio Passaro; Bruno Vincenzi; Fabian Acker; Lisa Derosa; David Planchard; Hugo J.W.L. Aerts; Silvia Novello; Francesco Passiglia; Carlo Greco; Sara Ramella; Alessio Cortellini展开收起
作者单位
Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Roma, Italy; Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; GROW Research Institute for Cancer and Reproduction, Maastricht University, Maastricht, The Netherlands; Department of Surgery and Cancer, Imperial College of London, London, United Kingdom; Medical Oncology, ASST Fatebenefratelli-Sacco, Milano, Italy; Department of Hematology-Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Section of Medical Oncology, Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut; Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts; Medical Oncology/TSET Phase 1 Program, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, Oklahoma; Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy; IRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele, Milan, Italy; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom The Christie NHS Foundation Trust, Manchester, United Kingdom; Department of Pulmonary Diseases, GROW—Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy; Department of Medicine II, Hematology and Oncology, University Hospital, Goethe University Frankfurt, Frankfurt, Germany; Tumor Immunology and Cancer Immunotherapy, Université Paris-Saclay, Gustave Roussy, Inserm UMR1015, Villejuif, France; Department of Medical Oncology, Gustave Roussy, Villejuif, France; Department of Medical Oncology, Thoracic Group, Gustave Roussy, Villejuif, France Faculty of Medicine, Paris-Saclay University, Paris, France; Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Harvard Institutes of Medicine, Boston, Massachusetts; Radiology and Nuclear Medicine, CARIM and GROW, Maastricht University, Maastricht, The Netherlands; Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Turin, Italy; Operative Research Unit of Radiation Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy展开收起
PDF源文件 DOI 网页
171 天

YAP1 Defines an Emergent, Plastic Population of Relapsed SCLC

作者
C. Allison Stewart; Kavya Ramkumar; Runsheng Wang; Yuanxin Xi; Alexa Halliday; Lixia Diao; Qi Wang; Alejandra Serrano; Sarah Groves; Simon Heeke; Azusa Tanimoto; Laura Kaiser; Whitney Lewis; Mukulika Bose; Pedro Rocha; Loukia Karacosta; Vito Quaranta; Jing Wang; Julie George; Luisa Maren Solis Soto; Bingnan Zhang; John V. Heymach; Lauren A. Byers; Carl M. Gay展开收起
作者单位
Department of Thoracic/Head & Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia; Department of Translational Genomics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Medical Oncology, Thoracic Tumors Unit, Vall d’Hebron University Hospital, Barcelona, Spain; Institute for Experiential AI, Northeastern University, Boston, Massachusetts; Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine and University Hospital Cologne, University Hospital of Cologne, Cologne, Germany展开收起
PDF源文件 DOI 网页
109 天

Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial

作者
Suresh Senan; Byoung Chul Cho; Konstantin K. Laktionov; Yoshitaka Zenke; Ki Hyeong Lee; Qiming Wang; Alejandro Navarro; Eva Lotte Buchmeier; Sema Sezgin Goksu; Andrzej Badzio; Anhui Shi; Davey B. Daniel; Milada Zemanova; Puneeth Iyengar; Luis Paz-Ares; Leah Szadkowski; Priti Chugh; W. Victoria Lai; David R. Spigel展开收起
作者单位
Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Federal State Budgetary Institution “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russia; National Cancer Center Hospital East, Kashiwa, Japan; Chungbuk National University Hospital, Cheongju, Republic of Korea; The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, People's Republic of China; Hospital Vall d'Hebron and Vall d’Hebron Institute of Oncology, Barcelona, Spain; Hospitals of the City of Cologne gGmbH, Cologne, Germany; Akdeniz University Medical Faculty, Antalya, Türkiye; Medical University of Gdansk, Gdansk, Poland; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, People's Republic of China; Tennessee Oncology PLLC, Nashville, Tennessee; First Faculty of Medicine, Charles University, and General University Hospital, Prague, Czech Republic; Memorial Sloan Kettering Cancer Center, New York, New York; Hospital Universitario 12 de Octubre, CNIO-H120 Lung Cancer Unit, Ciberonc and Universidad Complutense, Madrid, Spain; AstraZeneca, Mississauga, Ontario, Canada; AstraZeneca, Waltham, Massachusetts; AstraZeneca, New York, New York; Sarah Cannon Research Institute, Nashville, Tennessee展开收起
PDF源文件 DOI 网页
62 天

Consensus Statement on ctDNA Minimal Residual Disease Testing in Early Stage NSCLC: A Delphi Study by the Asian Thoracic Oncology Research Group

作者
Aaron C. Tan; Bin-Chi Liao; Molly Li; David Lee; Yuji Uehara; Lucksamon Thamlikitkul; Jia-Tao Zhang; Meimei Zheng; Chee Khoon Lee; Nick Pavlakis; Thomas John; Ross A. Soo; Anders Skanderup; Pei Jye Voon; Beung-Chul Ahn; Sehhoon Park; Hidetoshi Hayashi; Yasushi Goto; Hidehito Horinouchi; Yasushi Yatabe; Thanyanan Reungwetwattana; James Chih-Hsin Yang; Dong-Wan Kim; Tony Mok; Daniel S.W. Tan; Yi-Long Wu; Myung-Ju Ahn展开收起
作者单位
Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong SAR, China; Sunway Medical Centre, Kuala Lumpur, Malaysia; Department of Thoracic Oncology, National Cancer Centre Hospital, Chuo-ku, Tokyo, Japan; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People's Republic of China; NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Royal North Shore Hospital, Sydney, Australia; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore; Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A∗STAR), Singapore, Singapore; Department of Radiotherapy, Oncology and Palliative Care, Hospital Umum Sarawak, Kuching, Sarawak, Malaysia; Center for Lung Cancer, Division of Hematology and Oncology, Department of Internal Medicine, Research Institute and Hospital, National Cancer Center, Gyeonggi-do, Republic of Korea; Department of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan; Department of Diagnostic Pathology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Internal Medicine, Seoul National University Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Republic of Korea展开收起
PDF源文件 DOI 网页
110 天

Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial

作者
Benjamin Levy; Luis Paz-Ares; Chien-Chung Lin; Scott Herbert; Tsung-Ying Yang; Anthony Tolcher; Yanyan Lou; Yoshitaka Zenke; Diego Cortinovis; Enriqueta Felip; Manuel Domine; Konstantinos Leventakos; Emiliano Calvo; Atsushi Horiike; Edward Pan; Priyanka Basak; Daisy Lin; Wen Gu; Rachel Chiaverelli; Michael J. Chisamore; Yasushi Goto展开收起
作者单位
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Baltimore, Maryland; Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense & CiberOnc, Madrid, Spain; Department of Internal Medicine, National Cheng Kung University Hospital and Tainan Hospital, Ministry of Health and Welfare, Tainan City, Taiwan; Quantum, Santa Fe, New Mexico; Department of Chest Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; NEXT Oncology, San Antonio, Texas; Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Medical Oncology Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy; Medicine and Surgery Department, University of Milano-Bicocca, Milano, Italy; Vall d’Hebron Hospital Campus, Vall d’Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Spain; Department of Oncology, Hospital Universitario Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain; Department of Oncology, Mayo Clinic, Rochester, Minnesota; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan;; Daiichi Sankyo, Inc., Basking Ridge, New Jersey; Oncology Early Development – External Collaborations, Merck & Co., Inc., Rahway, New Jersey; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan展开收起
PDF源文件 DOI 网页

FAQ

Journal of Thoracic Oncology审稿要多久?

截至2026-11-19,CrushSCI 收录了 Journal of Thoracic Oncology 的 11 篇完整审稿记录。最快一篇从收稿到录用用了 12 天(Identifying Patients With High-Risk Stage I NSCLC Using a Tumor-Informed Plasma ctDNA Assay,2026-01-27 收稿,2026-02-08 录用),最慢一篇用了 245 天;平均 103.9 天,中位数 99 天。

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。